ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
9 announcements
Bharat Parenterals intimated that its Board will meet on 29 September 2026 to consider a preferential equity issue. The agenda item is proposed, not yet approved, with no amount disclosed.
Bharat Parenterals Limited has re-appointed Mr. Hemang Jayendrabhai Shah as Executive Director for a 5-year term effective July 2, 2026.
Bharat Parenterals Limited held its 33rd Annual General Meeting on September 19, 2026. The proceedings covered the adoption of financial statements and various resolutions.
Q1 FY27 consolidated revenue fell 19% YoY to ₹93.7 Cr due to standalone institutional order base effects. Gross margins expanded 1,000bps to 50.6%, though consolidated PAT remained negative at ₹(3.6) Cr.
Bharat Parenterals Ltd reported revenue from operations of ₹93.7 Cr (-19.2% YoY) and a net loss of ₹3.6 Cr for Q1 FY27.
Bharat Parenterals reported flat FY26 consolidated revenue of ₹345.4cr but a 6x EBITDA surge to ₹15.8cr. Transition year focused on regulatory clearances and scaling subsidiaries like Innoxel and Varenyam.
Bharat Parenterals calls FY26 a 'bridge year' of transition, clearing regulatory hurdles and scaling subsidiaries despite flat consolidated revenue of ₹345.4 cr. Growth in high-margin subsidiaries Inoxxel and Verineum offset a 23% decline in standalone exports.
Bharat Parenterals FY26 results show a transition phase with consolidated revenue of ₹345.4Cr and a PAT loss of ₹27.3Cr, driven by heavy R&D and subsidiary investment.
Bharat Parenterals Ltd reported revenue from operations of ₹99.6 Cr (-4.2% YoY) and a net loss of ₹8.2 Cr for Q4 FY26.